Pancreatic cancers overexpress epidermal growth factor (EGFR), and the presence of this receptor has been shown to correlate with negative outcomes.[6–10] After ligand activation, members of the EGFR family dimerize, trans-autophosphorylate each other, and subsequently activate a wide variety of downstream signals controlling cell proliferation, resistance to apoptosis, invasion, angiogenesis and metastasis.[11] Erlotinib is an orally administered human EGFR tyrosine kinase inhibitor which prevents autophosphorylation of the receptor dimer and activation of downstream targets. This evidence concerns the gene EGFR and pancreatic neoplasm.